FOLR1 and neoplasm: Preclinical studies on the T47D human breast cancer cell line and T47D tumor-bearing mice, which delivered 23.97 ± 2.1 Gy after 74 MBq injection, with precise Micro-SPECT/CT imaging, demonstrating the promising potential of [177Lu]Lu-Folate-BN as a theranostic radiopharmaceutical due to their concomitant identification of GRPR and FRα.